Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00511381 · ClinicalTrials.gov registry record
Genetic Testing in Detection of Late-Onset Hearing Loss
A clinical trial, sponsored by Pediatrix.
- Completed
- Registry status
- 3,681
- Enrollment target
NCT00511381: Completed study, sponsored by Pediatrix.
NCT00511381 is a clinical trial that has completed, run by Pediatrix. The registered enrollment target is 3,681 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00511381 has completed, sponsored by Pediatrix.
- COMPLETED
- Registry status
- 3,681 participants
- Enrollment target
Study Summary
Two major limitations of existing audiometric newborn hearing screening programs are their inability to detect forms of deafness that are not expressed at birth and the low compliance with obtaining recommended audiologic confirmation and/or follow-up. Molecular genetic tests on blood spots from all newborns will identify those at risk for the most frequent causes of late-onset hearing loss and to add these infants to the group who should receive continued audiologic monitoring.
Interventions
- GENETIC No intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,681 participants |
| Start Date | 2007-10 |
| Est. Completion | 2011-09 |
What the finished NCT00511381 record still lists
NCT00511381 is an observational study that tracks outcomes without assigning an intervention. Its 3,681 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which No intervention is the first listed.
NCT00511381 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00511381 about?
NCT00511381 is a clinical study titled "Genetic Testing in Detection of Late-Onset Hearing Loss". Two major limitations of existing audiometric newborn hearing screening programs are their inability to detect forms of deafness that are not expressed at birth and the low compliance with obtaining recommended audiologic confirmation and/or follow-up. Molecular genetic tests on blood spots from all...
What is the current status of trial NCT00511381?
This trial is currently completed. The enrollment target is 3,681 participants. The study started on 2007-10. Estimated completion is 2011-09.
What interventions are being tested in trial NCT00511381?
The interventions under investigation include: No intervention (GENETIC).
Who is sponsoring clinical trial NCT00511381?
This trial is sponsored by Pediatrix, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06058377 · 3,680 participants · Phase 3
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
- NCT06784960 · 3,689 participants · NA
Communication Strategies to Increase HPV Vaccination Intention
- NCT06401863 · 3,691 participants · NA
Shared Decision for Drug Interactions in Oral Anticoagulation
- NCT06702553 · 3,650 participants · Phase 3
Nitric Oxide for Reduced Intensive Support in Cardiac Surgery With Cardiopulmonary Bypass
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia